ReviewThe Biochemical journal2000
Tetrahydrobiopterin biosynthesis, regeneration and functions.
Review in The Biochemical journal, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 334 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
334 citing papers in PubMed, 2 syntheses or guidelines pooled it, 849 citations in OpenAlex.
- Autosomal Recessive Guanosine Triphosphate Cyclohydrolase I Deficiency: Redefining the Phenotypic Spectrum and Outcomes.Movement disorders clinical practice · 2024Pooled it
- A meta-analysis of two high-risk prospective cohort studies reveals autism-specific transcriptional changes to chromatin, autoimmune, and environmental response genes in umbilical cord blood.Molecular autism · 2019Pooled it
- No effect of acute tetrahydrobiopterin (BHJournal of applied physiology (Bethesda, Md. : 1985) · 2022Trial
- Genome-integrated engineering ofSynthetic and systems biotechnology · 2027Article
- Engineering a heme-dependent tryptophan hydroxylase pathway inSynthetic and systems biotechnology · 2026Article
- Comparative Transcriptome Analysis Reveals Tissue-Specific Expression and Conservation of Mitochondrial Metal and Cofactor Genes in Buffalo.Cell biochemistry and biophysics · 2026Article
- A Cross-Sectional Study on Immune-Inflammatory Responses: Exposure to Polycyclic Aromatic Hydrocarbons Alters Pteridine Metabolism and Activates the Kynurenine Pathway.Chemical research in toxicology · 2026Article
- Emerging roles of pterins as signaling molecules in bacteria.Biochemical Society transactions · 2026Review
- Attenuation of Triple Selection Markers to Enhance mAb Expression in Tyrosine-Based Selection Systems via an Inducible CRISPRi Platform.Biotechnology journal · 2026Article
- Nitrogen-containing FDA-approved drugs in 2025: synthesis, significance and therapeutic applications.RSC advances · 2026Review
- Skin Colour in Salamanders Is Modulated by Both Epitranscriptomic Methylation and Gene Expression.Molecular ecology · 2026Article
- Metabolic characteristics in hepatocellular carcinoma: amino acid metabolic reprogramming.Molecular cancer · 2026Review
- Targeting Oxidative and Nitrosative Stress: Mechanistic Insights and Therapeutic Strategies for Radiation-Induced Lung Injury.Journal of inflammation research · 2026Review
- Article
- Multivariate genome-wide analysis reveals shared genetic architecture and brain structural correlates of human cognitive abilities.Scientific reports · 2025Article
- Mechanism of soil bacteria (Cupriavidus sp. LA-1) for degrading natural pterin and lumazine pigments.Communications biology · 2025Article
- Resolution of Lipopolysaccharide-Induced Inflammation Followed by DNA Hypomethylation and Increased Tetrahydrobiopterin Biosynthesis in Mouse Hippocampus.Brain sciences · 2025Article
- CRISPR-Cas9-based one-step multiplexed genome editing through optimizing guide RNA processing strategies inSynthetic and systems biotechnology · 2025Article
- Designing pathways for bioproducing complex chemicals by combining tools for pathway extraction and ranking.Nature communications · 2025Article
- Untargeted metabolomics reveals stage-specific metabolic signatures in yak colostrum, transitional milk and mature milk.Food chemistry: X · 2025Article
274 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tetrahydrobiopterin (BH(4)) cofactor is essential for various processes, and is present in probably every cell or tissue of higher organisms. BH(4) is required for various enzyme activities, and for less defined functions at the cellular level. The pathway for the de novo biosynthesis of BH(4) from GTP involves GTP cyclohydrolase I, 6-pyruvoyl-tetrahydropterin synthase and sepiapterin reductase. Cofactor regeneration requires pterin-4a-carbinolamine dehydratase and dihydropteridine reductase. Based on gene cloning, recombinant expression, mutagenesis studies, structural analysis of crystals and NMR studies, reaction mechanisms for the biosynthetic and recycling enzymes were proposed. With regard to the regulation of cofactor biosynthesis, the major controlling point is GTP cyclohydrolase I, the expression of which may be under the control of cytokine induction. In the liver at least, activity is inhibited by BH(4), but stimulated by phenylalanine through the GTP cyclohydrolase I feedback regulatory protein. The enzymes that depend on BH(4) are the phenylalanine, tyrosine and tryptophan hydroxylases, the latter two being the rate-limiting enzymes for catecholamine and 5-hydroxytryptamine (serotonin) biosynthesis, all NO synthase isoforms and the glyceryl-ether mono-oxygenase. On a cellular level, BH(4) has been found to be a growth or proliferation factor for Crithidia fasciculata, haemopoietic cells and various mammalian cell lines. In the nervous system, BH(4) is a self-protecting factor for NO, or a general neuroprotecting factor via the NO synthase pathway, and has neurotransmitter-releasing function. With regard to human disease, BH(4) deficiency due to autosomal recessive mutations in all enzymes (except sepiapterin reductase) have been described as a cause of hyperphenylalaninaemia. Furthermore, several neurological diseases, including Dopa-responsive dystonia, but also Alzheimer's disease, Parkinson's disease, autism and depression, have been suggested to be a consequence of restricted cofactor availability.
Indexed as
Identifiers
10727395PMC1220924W2128399345What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.